ARPP19

Across TCGA pan-cancer cohorts, ARPP19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARPP19 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARPP19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARPP19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where ARPP19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.152	0.973	.017	30	view →
CCRCC	DFS	Tertile	II,III,IV	0.902	0.560	.007	17	view →
LUAD	DFS	Quartile	III,IV	0.560	1.000	.040	6	view →
PDAC	OS	Median	IV	0.540	0.951	.017	5	view →
LSCC	OS	Tertile	III,IV	0.683	0.986	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARPP19–HNSC (OS)

Open the HNSC breakdown →